Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7657005 | 0.88 | MAPT (0.37) | MAPTASH1LTDP1CAMK2D | |
| Acetic Acid SCHEMBL7815326 | 0.87 | MAPT (0.41) | MAPTASH1LTDP1KDM4ESMN1; SMN2 | |
| Acetic Acid SCHEMBL8366763 | 0.87 | MAPT (0.38) | MAPTASH1LTDP1KDM4EHTT | |
| SCHEMBL7850355 | 0.86 | CAMK2D (0.44) | CAMK2D | |
| SCHEMBL7657255 | 0.86 | MAPT (0.34) | MAPTASH1LTDP1HTTSMN1; SMN2 | |
| Acetic Acid SCHEMBL7817159 | 0.86 | MAPT (0.37) | MAPTASH1LTDP1ALDH1A1 | |
| Acetic Acid SCHEMBL7663687 | 0.86 | MAPT (0.41) | MAPTASH1LTDP1CAMK2D | |
| Acetic Acid SCHEMBL7657247 | 0.85 | ASH1L (0.37) | MAPTASH1LTDP1KDM4EALDH1A1 | |
| Acetic Acid SCHEMBL7654036 | 0.85 | ASH1L (0.36) | MAPTASH1LTDP1CAMK2D | |
| SCHEMBL7654047 | 0.84 | ASH1L (0.35) | MAPTASH1LTDP1CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |